Roxee Meds Catalog

Trilostane

Medication catalog facts with explicit FDA-approval, off-label, source-limited, and safety context.

Dog Catalog complete FDA data linked Rx required Capsule Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Storefront facts

Catalog refreshed

May 5, 2026, 10:00 a.m.

These are the storefront facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

May 5, 2026, 10:00 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

May 5, 2026, 10:01 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
The storefront fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Evidence

Reviewed / Updated / Sources

Reviewed by: Not available

Last reviewed: February 12, 2026

Updated: February 12, 2026, 7:40 PM UTC

Sources:

FDA application profile · official_label
Medication usage source · fda_animal_drugs
openFDA case USA-USFDACVM-2025-US-069486 · adverse_reaction
FOI · document
FOI · document

Image coming soon

Trilostane

Drug type: Generic ingredient • Branded profile • FDA branded products available

Dog Capsule Rx required 100% storefront ready

Species: Dog

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Trilostane

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks. Species commonly shown: Dog, Dog, No Use Class Stated Or Implied.

Generic name

Trilostane

Brand names

VETORYL® CAPSULES, Vetoryl, TRILOSTANE, X

Manufacturer

Multiple FDA labelers

Species

Dog, Dog, No Use Class Stated Or Implied

Dosage forms

Capsule

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

VETORYL® CAPSULES Vetoryl TRILOSTANE X AX Pharmaceutical Corp

Dosage forms

Capsule

Indications / Uses

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.

Administration / How To Give

Oral

Storage

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Warnings / Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Side Effects

Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.

FAQ

Dog, Dog, No Use Class Stated Or Implied

Yes. Roxee shows this as prescription-only.

Capsule

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Related Medications

Related Conditions

Hyperadrenocorticism (Cushing’s) Cushing’s Disease (Hyperadrenocorticism) Cushing’s Disease (Hyperadrenocorticism)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: /static/meds/images/trilostane.jpg
Last refreshed: May 5, 2026, 10:00 a.m.
Last verified: Feb 12, 2026, 7:40 p.m.
Validation status: Complete

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches
Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors
Hearing affected (1 reports)
Haematuria (1 reports)
Gastrointestinal irritation (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Major cautions & emergency warning signs

Side effects to monitor:

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches
Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors
Hearing affected
Haematuria
Gastrointestinal irritation

Most reported reactions:

Hearing affected (1 reports)
Haematuria (1 reports)
Gastrointestinal irritation (1 reports)

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Dog

Manufacturer: Multiple FDA labelers

Form: Capsule

Identifiers:

NADA: 141291 NDC Package: 17033-105-30 NDC Package: 17033-110-30 NDC Package: 17033-111-30 NDC Package: 17033-112-30 NDC Package: 17033-130-30 NDC Package: 17033-160-30 NDC Package: 58597-7038-6 NDC Package: 62157-361-01 NDC Package: 62157-401-01 NDC Package: 62157-556-01 NDC Package: 62157-557-01 NDC Package: 62157-560-01 NDC Package: 62157-596-01 NDC Package: 62157-927-01 NDC Package: 62991-2736-1 NDC Package: 62991-2736-2 NDC Package: 62991-2736-3 NDC Package: 62991-2736-4 NDC Package: 62991-2736-5

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/141291 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

High: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (4) · Loss of appetite, Diarrhea, Decreased appetite Skin & allergy (1) · Head twitching Behavior (1) · Behavioral disorder (unspecified) Other (26) · Hearing affected, Haematuria, General illness

Most Reported Reactions

Body system	Cases	Species	Serious cases
Other	1	Dog	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Dog	1
Other	1	Cat	1

Species coverage: Dog (19) Cat (13)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Digestive	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Skin & allergy	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Dog	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Non-serious	-	1
Behavior	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Non-serious	-	1
Other	Dog	Non-serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-069486

Storage & Handling

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Documents

Owner handouts and official technical documents open on-page first, with the original source still one click away.

Owner handouts

No owner handouts linked yet.

Official label / PI

SPL

FOI

VETORYL N141291C0048.pdf

Official label / PI · Labeling

Open original

VETORYL® CAPSULES

SPL · SPL

Open original

FDA Structured Product Label

VETORYL® CAPSULES

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Dechra, Ltd.
NADA: 141-291
Status: RX
Form: Capsule
Route: Oral
Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each capsule contains 5, 10, 20, 30, 60, or 120 mg trilostane.

Dogs

UCM173123.pdf

FOI · FOI

Open original

UCM508381.pdf

FOI · FOI

Open original

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/856 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/855 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/914 · document · Labeling
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2017/VETORYL%C2%AE%20CAPSULES · document · SPL
https://www.accessdata.fda.gov/spl/data/bd827b0b-7a67-4b30-936e-063c7c7a9d4f/bd827b0b-7a67-4b30-936e-063c7c7a9d4f.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/e7596834-ad63-4e37-b1f4-390fdff15fa4/e7596834-ad63-4e37-b1f4-390fdff15fa4.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/45b40fc8-9e1a-4c47-b1a9-ffabfc9f5f04/45b40fc8-9e1a-4c47-b1a9-ffabfc9f5f04.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/d23b1adb-887c-414d-8417-7886d94278d3/d23b1adb-887c-414d-8417-7886d94278d3.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/6409a33f-ec4a-422b-a0e0-1d06a9f09149/6409a33f-ec4a-422b-a0e0-1d06a9f09149.xml · document · Structured Product Label
https://www.accessdata.fda.gov/spl/data/f8485369-2c18-475e-bc41-f00a19b89a8e/f8485369-2c18-475e-bc41-f00a19b89a8e.xml · document · Structured Product Label

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Storefront facts: Source Roxee | Refreshed May 5, 2026, 10:00 AM UTC
The storefront fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed May 5, 2026, 10:00 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed May 5, 2026, 10:04 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: AX Pharmaceutical Corp TRILOSTANE Trilostane Vetoryl X

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Dog • FDA-labeled species: Dog

Rx/OTC: RX

Form/route: Capsule • Oral

Applications: NADA 141-291

NDC: Packages 17033-105-30 17033-110-30 17033-111-30 17033-112-30 17033-130-30 17033-160-30 • Products 17033 58597 62157 62991 63732 69182

Documents: 3 (FOI: 2) • SPL: 1 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 25 • Cat 6 • View

Case summaries: 12 (showing 8) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Hyperadrenocorticism (Cushing’s) Cushing’s Disease (Hyperadrenocorticism) Cushing’s Disease (Hyperadrenocorticism)

Linked using: Fda_Label (0.95), Usage_Inferred (0.78), Usage_Inferred (0.78)

Diagnosis Codes

ICD10_CM: E24.9

Cushing syndrome, unspecified

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors. (Contraindication, High)

Top reaction signals

Hearing affected (1) Haematuria (1) Gastrointestinal irritation (1) Enlarged kidney (1) Elevated serum alkaline phosphatase (1) Elevated alanine aminotransferase (1) Ear infection NOS (1) Drug prescribing error (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
17033-105-30	17033	-
17033-110-30	17033	-
17033-111-30	17033	-
17033-112-30	17033	-
17033-130-30	17033	-
17033-160-30	17033	-
58597-7038-6	58597	-
62157-361-01	62157	-
62157-401-01	62157	-
62157-556-01	62157	-
62157-557-01	62157	-
62157-560-01	62157	-
62157-596-01	62157	-
62157-927-01	62157	-
62991-2736-1	62991	-
62991-2736-2	62991	-
62991-2736-3	62991	-
62991-2736-4	62991	-
62991-2736-5	62991	-
63732-2018-4	63732	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
TRILOSTANE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Vetoryl SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
X SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Trilostane SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
AX Pharmaceutical Corp SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
X SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
TRILOSTANE SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
VETORYL N141291C0048.pdf • Official label • Official • May 20, 2024
FDA official labeling for application 141291
UCM508381.pdf • FOI summary • Official • May 20, 2024
FDA FOI summary for application 141291
UCM173123.pdf • FOI summary • Official • May 20, 2024
FDA FOI summary for application 141291

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 58 Clinical 7 Manufacturer 0 Marketing 0

Current Field Facts

overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-04-12)
overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-04-11)
overdose_info: Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluid… (Clinical, 2026-02-12)
side_effects: Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed. (Clinical, 2026-04-11)
storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-04-12)
storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-04-11)
storage_handling: Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and … (Clinical, 2026-02-12)
contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-04-12)
contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-04-11)
contraindications: Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE … (Official, 2026-02-12)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-05-05)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-05-03)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-05-02)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-04-29)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-04-28)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-04-27)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-04-26)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-04-25)
indications: For the treatment of pituitary-dependent hyperadrenocorticism in dogs and for the treatment of hyperadrenocorticism due to adrenocortical tumor in dogs. (Official, 2026-04-22)
manufacturer_name: Multiple FDA labelers (Official, 2026-05-05)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 19:40 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
VETORYL® CAPSULES RX Trilostane Capsule • Oral Label highlights Official documents	Dechra, Ltd.	NADA 141-291	Approved	May 20, 2024

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog, No Use Class Stated Or Implied

Composition / specifications

Each capsule contains 5, 10, 20, 30, 60, or 120 mg trilostane.

Dogs

Indication

For the treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism in dogs.

Dosage

The starting dose for the treatment of hyperadrenocorticism in dogs is 1.0 to 3.0 mg/lb (2.2 to 6.7 mg/kg) once a day based on body weight and capsule size. Capsules should be administered with food.

Limitations

FDA page: Open in Animal Drugs @ FDA

Usage

Used to treat hyperadrenocorticism (Cushing’s disease) in dogs by inhibiting cortisol production. Requires regular monitoring via ACTH stimulation tests and electrolyte checks.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Do not use in dogs with acute or serious liver/kidney disease or in pregnant bitches. Avoid use with potassium-sparing diuretics and exercise caution with ACE inhibitors.

Side Effects

Common side effects include decreased appetite, vomiting, diarrhea, and lethargy; may lead to an Addisonian crisis if cortisol is overly suppressed.

Source: FDA openFDA • Reference

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Loss of appetite (1) • Dog Diarrhea (1) • Dog Decreased appetite (1) • Cat Appetite loss (1) • Dog

Showing top 5 for Digestive.

Skin & allergy

Head twitching (1) • Dog

Showing top 5 for Skin & allergy.

Behavior

Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Other

Hearing affected (1) • Dog Haematuria (1) • Cat General illness (1) • Dog Gastrointestinal irritation (1) • Dog Error occurred in home (1) • Cat

Show more (21)

Enlarged kidney (1) • Cat Elevated serum alkaline phosphatase (1) • Dog Elevated blood urea nitrogen (1) • Dog Elevated alanine aminotransferase (1) • Dog Ear infection NOS (1) • Dog Drug prescribing error (1) • Cat Dilated renal pelvis (1) • Cat Diabetes mellitus (1) • Cat Dermal mass (1) • Dog Death by euthanasia (1) • Cat Death (1) • Dog Collapse NOS (1) • Dog Cataract (1) • Dog Blood in urine (1) • Dog Barking (1) • Dog Azotaemia (1) • Cat Anisocoria (1) • Cat Accidental exposure (1) • Cat Abnormal ultrasound finding (1) • Cat Abnormal movement NOS (1) • Dog Abnormal adrenocorticotropic hormone (ACTH) stimulation test (1) • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Terrier - Boston, Male, 10 year, 16.14 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 12 per hour • Reactions: Skin disorders NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075125
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 10.00 Year
Weight: 16.140 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 20 Milligram per animal
Frequency: 12 per hour

Reactions Reported:

Skin disorders NOS

Outcomes: Outcome Unknown

Dog, Spaniel - King Charles Cavalier, Male, 14 year, 12.1 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 12 per hour • Reactions: Ear infection NOS, Polyp, Decreased appetite • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075124
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 14.00 Year
Weight: 12.100 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 5 Milligram per animal
Frequency: 12 per hour

Reactions Reported:

Ear infection NOS Polyp Decreased appetite

Outcomes: Outcome Unknown

Dog, Spaniel (unspecified), Female, 8.6 year, 13 kilogram • Drug: MSK, Capsule, Oral, Dose: 5 Milligram per animal, Frequency: 12 per hour • Reactions: Diabetes mellitus, Hyperglycaemia, Cataract • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-075123
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 8.60 Year
Weight: 13.000 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 5 Milligram per animal
Frequency: 12 per hour

Reactions Reported:

Diabetes mellitus Hyperglycaemia Cataract

Outcomes: Ongoing

Dog, ['Dachshund - Standard Long-haired', 'Dog (unknown)'], Female, 11 year, 9 kilogram • Drug: MSK, Capsule, Oral, Dose: 15 Milligram per animal, Frequency: 24 per hour • Reactions: Hyperglycaemia • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075122
Serious AE: No
Treated For AE: No
Sex: Female
Age: 11.00 Year
Weight: 9.000 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 15 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Hyperglycaemia

Outcomes: Outcome Unknown

Dog, ['Terrier - Silky', 'Dog (unknown)'], Male, 13.5 year, 6.078 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 12 per hour • Reactions: Diarrhea, Polyuria, Hyperglycaemia, Elevated blood urea nitrogen, Hyperkalaemia… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075121
Serious AE: No
Treated For AE: No
Sex: Male
Age: 13.50 Year
Weight: 6.078 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 10 Milligram per animal
Frequency: 12 per hour

Reactions Reported:

Diarrhea Polyuria Hyperglycaemia Elevated blood urea nitrogen Hyperkalaemia Low sodium-potassium ratio

Outcomes: Outcome Unknown

Dog, Greyhound, Male, 11 year, 30.9 kilogram • Drug: MSK, Capsule, Oral, Dose: 20 Milligram per animal, Frequency: 24 per hour • Reactions: Decreased appetite, Lack of efficacy - NOS • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075120
Serious AE: No
Treated For AE: No
Sex: Male
Age: 11.00 Year
Weight: 30.900 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 20 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Decreased appetite Lack of efficacy - NOS

Outcomes: Outcome Unknown

Dog, Greyhound - Italian, Female, 9 year, 5.18 kilogram • Drug: MSK, Capsule, Oral, Dose: 30 Milligram per animal, Frequency: 24 per hour • Reactions: Weight loss, Inappetence • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-075119
Serious AE: No
Treated For AE: No
Sex: Female
Age: 9.00 Year
Weight: 5.180 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 30 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Weight loss Inappetence

Outcomes: Outcome Unknown

Dog, ['Maltese', 'Poodle - Miniature'], Female, 13 year, 4.75 kilogram • Drug: MSK, Capsule, Oral, Dose: 10 Milligram per animal, Frequency: 24 per hour • Reactions: Elevated serum alkaline phosphatase, Seizure NOS, Hypocortisolaemia, Abnormal adrenocorticotropic hormone (ACTH) stimulation test, Syncope… • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-074687
Serious AE: Yes
Treated For AE: No
Sex: Female
Age: 13.00 Year
Weight: 4.750 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Capsule
Dose: 10 Milligram per animal
Frequency: 24 per hour

Reactions Reported:

Elevated serum alkaline phosphatase Seizure NOS Hypocortisolaemia Abnormal adrenocorticotropic hormone (ACTH) stimulation test Syncope Barking Lying down

Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

Overdose can cause acute adrenal insufficiency with signs of collapse, severe weakness, and gastrointestinal upset. Immediate emergency treatment with IV fluids and corticosteroids is required.

Storage & Handling

Store at controlled room temperature (25°C / 77°F) with excursions allowed between 15–30°C (59–86°F). Keep capsules in original container, tightly closed, and handle with care.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Trilostane

Data freshness

Evidence

Trilostane

Medication Snapshot

Trilostane

Indications / Uses

Administration / How To Give

Storage

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

How should this be stored?

Related Medications

Related Conditions

Source Transparency

Add to My Pet's Meds

Pet Owner Quick Guide

Quick Facts

Warnings / Contraindications

Adverse Reactions

Grouped by Body System

Most Reported Reactions

Storage & Handling

Documents

Owner handouts

Official label / PI

SPL

FOI

VETORYL N141291C0048.pdf

VETORYL® CAPSULES

VETORYL® CAPSULES

Dogs

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

Trilostane SPL

TRILOSTANE SPL

Vetoryl SPL

Trilostane SPL

X SPL

AX Pharmaceutical Corp SPL

Trilostane SPL

AX Pharmaceutical Corp SPL

AX Pharmaceutical Corp SPL

AX Pharmaceutical Corp SPL

X SPL

TRILOSTANE SPL

UCM173123.pdf

UCM508381.pdf

At a Glance

Counseling and Monitoring Highlights

Identifiers & Packages

Enriched Documents

Data Sources & Change Log

FDA Products & Applications (Animal Drugs @ FDA)

What It's For (FDA Label Highlights)

VETORYL® CAPSULES • Capsule • Oral

Usage

Contraindications

Side Effects

Top Reported Reactions (openFDA)

Adverse Event Case Summaries (openFDA)

Dec 16, 2025 • Dog • Terrier - Boston • Skin disorders NOS • Outcome Unknown

Dec 16, 2025 • Dog • Spaniel - King Charles Cavalier • Ear infection NOS, Polyp • Outcome Unknown

Dec 16, 2025 • Dog • Spaniel (unspecified) • Diabetes mellitus, Hyperglycaemia • Ongoing

Dec 16, 2025 • Dog • ['Dachshund - Standard Long-haired', 'Dog (unknown)'] • Hyperglycaemia • Outcome Unknown

Dec 16, 2025 • Dog • ['Terrier - Silky', 'Dog (unknown)'] • Diarrhea, Polyuria • Outcome Unknown

Dec 16, 2025 • Dog • Greyhound • Decreased appetite, Lack of efficacy - NOS • Outcome Unknown

Dec 16, 2025 • Dog • Greyhound - Italian • Weight loss, Inappetence • Outcome Unknown

Dec 11, 2025 • Dog • ['Maltese', 'Poodle - Miniature'] • Elevated serum alkaline phosphatase, Seizure NOS • Outcome Unknown

Overdose Information